DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

1 hour ago 1

MarketBeat

Sat, May 16, 2026 astatine 8:08 AM CDT 8 min read

Key Points

Interested successful DexCom, Inc.? Here are 5 stocks we similar better.
DexCom outlined a semipermanent maturation plan targeting much than 10% yearly gross maturation done 2030, on with borderline enlargement and stronger currency flow. Management besides said it plans to repurchase $1 cardinal of banal successful 2026 and instrumentality astatine slightest 50% of yearly escaped currency travel to buybacks going forward.
Product improvement is centered connected G7 15 Day and next-generation G8, with G7 15 Day rolling retired successful the U.S. and internationally aboriginal this year. DexCom said G8 could motorboat astir precocious 2027 oregon aboriginal 2028 and is designed to beryllium 50% smaller, much accurate, and little outgo to marque than G7.
Coverage enlargement is simply a large catalyst, particularly for benignant 2 diabetes patients not utilizing insulin. DexCom expects Medicare sum decisions, broader U.S. payer adoption, and planetary reimbursement gains to assistance covered lives importantly implicit the adjacent fewer years.

Sell successful May and Go Away—Starting With These 3 Stocks

DexCom (NASDAQ:DXCM) utilized its 2026 Investor Day to outline a long-range program centered connected caller merchandise launches, broader security sum for continuous glucose monitoring, planetary enlargement and borderline improvement.

President and Chief Executive Officer Jake Leach said the company’s adjacent signifier volition beryllium driven by an precocious merchandise portfolio, increasing objective and economical grounds supporting CGM access, and scalable solutions that absorption believes tin enactment durable double-digit maturation and beardown currency travel generation.

→ Micron Investors Face a High-Stakes Moment After the Latest Rally

3 Reasons Analysts Love DexCom

Leach said Dexcom served much than 3.5 cardinal patients astatine the extremity of past year, up from 900,000 successful 2020, and grew gross to $4.6 cardinal past year. He said the institution is operating astatine margins supra 20%, with “additional country to go.”

Dexcom Highlights Product Roadmap, Including G8

Leach said Dexcom precocious launched its G7 15 Day merchandise successful the U.S., with an optimized algorithm and extended deterioration time. He said the rollout is proceeding arsenic expected, with the institution connected way to person astir fractional of its U.S. basal to the merchandise by the extremity of the year. Dexcom besides present has Tandem compatibility for the 15-day product, joining Beta Bionics and Insulet, helium said.

→ How Bad Could Tesla’s Cybertruck Recall Be for Shares?

From Dividends to Growth: Why These 3 Stocks Stand Out successful 2025

The institution plans to statesman rolling retired G7 15 Day internationally successful the 2nd fractional of this year, taxable to regulatory approvals. Leach said 15-day sensor deterioration volition go the baseline for aboriginal products.

Read Entire Article